SAB Biotherapeutics (NASDAQ:SABS) Releases Quarterly Earnings Results, Misses Expectations By $0.05 EPS

SAB Biotherapeutics (NASDAQ:SABS) posted its quarterly earnings data on Wednesday. The company reported ($1.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.05), Zacks reports. SAB Biotherapeutics had a negative net margin of 1,450.14% and a negative return on equity of 94.04%.

SAB Biotherapeutics Price Performance

Shares of NASDAQ:SABS traded down $0.68 during mid-day trading on Thursday, hitting $3.27. The company had a trading volume of 112,123 shares, compared to its average volume of 138,942. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.24 and a current ratio of 5.24. SAB Biotherapeutics has a one year low of $2.16 and a one year high of $9.72. The firm has a fifty day moving average price of $2.89 and a 200 day moving average price of $3.02.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on SABS shares. Oppenheimer reaffirmed an “outperform” rating and issued a $12.00 price objective on shares of SAB Biotherapeutics in a research note on Thursday, September 12th. Chardan Capital restated a “buy” rating and issued a $25.00 price target on shares of SAB Biotherapeutics in a research report on Thursday. Craig Hallum assumed coverage on shares of SAB Biotherapeutics in a research report on Wednesday, October 9th. They set a “buy” rating and a $11.00 price objective for the company. Finally, HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of SAB Biotherapeutics in a report on Monday, August 12th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $12.40.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.